Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Grail
ISIN US3847471014
|WKN A40F8M
Market cap (in EUR)
1,422 m
Country
United States
Sector
Healthcare
Overview
Description
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
Healthcare Healthcare Equipment Diagnostics and Drug Delivery Devices United States
Financials
Key metrics
| Market capitalisation, EUR | 1,422 m |
| EPS, EUR | -9.91 |
| P/B ratio | 0.7 |
| P/E ratio | - |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | 130 m |
| Net income, EUR | -362 m |
| Profit margin | -277.47% |
What ETF is Grail in?
There are 2 ETFs which contain Grail. All of these ETFs are listed in the table below. The ETF with the largest weighting of Grail is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.31% | Equity United States Health Care Biotech | 48 |
| JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) | 0.05% | Equity United States Small Cap | 190 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.